title: Ly-6A/E gene is widely expressed among transformed nonhematopoietic cells. Autocrine modulation by interferon.
abstract: Expression of the Ly-6A/E gene by transformed cells was investigated in 14 cell cultures of C57BL/6 and BALB/c mouse origin derived from spontaneous or chemically-induced non-hematopoietic tumours and from cells transformed by SV40 virus. Histologic types included carcinomas, sarcomas and a melanoma. Thirteen out of 14 cell cultures expressed membrane Ly-6A/E antigens; only the B16-A melanoma was negative, but it expressed Ly-6A/E after incubation with IFN-gamma. The effect of in vitro permanence was studied on early (< 10) and late (> 20) passages of B16-A melanoma and MN/MCA1 fibrosarcoma. Late passage B16-A cells were Ly-6A/E-negative and refractory to induction of Ly-6A/E (but not of H-2 antigens) by IFN-alpha, IFN-beta, or IFN-gamma; MN/MCA1 maintained a high expression of Ly-6A/E, but no increase was induced by IFNs. It was found that both early and late in vitro passages of MN/MCA1 actively produced IFN-alpha/beta. The analysis of cells of fibroblastic origin revealed a significant correlation between IFN release in the culture medium and Ly-6A/E levels. Culture of fibrosarcoma cells in the presence of an anti-IFN-alpha/beta serum reduced Ly-6A/E expression, thus indicating the existence of an autocrine loop.
authors.affiliation: Istituto di Cancerologia, Università di Bologna, Italy.
authors.forename: P L
authors.initials: PL
authors.lastname: Lollini
authors.forename: L
authors.initials: L
authors.lastname: Landuzzi
authors.forename: G
authors.initials: G
authors.lastname: Nicoletti
authors.forename: C
authors.initials: C
authors.lastname: de Giovanni
authors.forename: M
authors.initials: M
authors.lastname: Giovarelli
authors.forename: E
authors.initials: E
authors.lastname: Lalli
authors.forename: A
authors.initials: A
authors.lastname: Facchini
authors.forename: P
authors.initials: P
authors.lastname: Nanni
mesh_terms: D000818:Animals; D002460:Cell Line; D002461:Cell Line, Transformed; D003110:Colonic Neoplasms; D015870:Gene Expression / Q000187:drug effects; D017261:Glycosylphosphatidylinositols / Q000235:genetics*; D016898:Interferon-alpha / Q000096:biosynthesis / Q000494:pharmacology*; D016899:Interferon-beta / Q000096:biosynthesis / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D008546:Melanoma, Experimental; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins; D012044:Regression Analysis; D012513:Sarcoma, Experimental; D014407:Tumor Cells, Cultured
chemical_list: D017261:Glycosylphosphatidylinositols; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016899:Interferon-beta; D007371:Interferon-gamma